RE:RE:Market cap 37 million hahahahThis morning CGON has an enterprise value of $1.6 billion USD. That's 40x TLT.v valuation. I think TLT has better technology that can be utilized for many cancer indications. Once FDA grants BTD that difference in valuation will gradually or suddenly disappear.
reconsider wrote: FUSN had a market cap of 200M 6 months before AstraZeneca announced its aquisition for $2.4B.
If Theralase's Rutherrin is real, we won't be trying to cut a deal with just one company. No pharma will be thinking of letting us drown while scaling up. Before that, another pharma would snatch us.
Q3 and the clock is ticking.